![]() | |
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.041.739 |
Chemical and physical data | |
Formula | C22H31N3O5 |
Molar mass | 417.506 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Cinepazide or cinepazide maleate [1] (Kelinao or Anjieli in China [2] [3]) is a vasodilator used in China for the treatment of cardiovascular and cerebrovascular diseases, and peripheral vascular diseases. [4] It appears to work by potentiating A2 adenosine receptors. [5]
Cinepazide was discovered by scientists at Laboratoires Delalande (now part of Sanofi) in 1969 in an effort to explore useful substituted cinnamoyl- piperazine compounds. [6] [7] The drug, in the form of a pill taken orally, was launched by Delalande in 1976 under the tradename Vasodistal, for treatment of heart failure, balance disorders, cerebrovascular disease, and vascular complications of diabetes. [6] [8] In 1988 the drug was withdrawn from the market in Spain due to risk of agranulocytosis; other countries where the drug was available added warnings to the label. [9] [10] It was withdrawn from the market in France in 1992. [11] The drug had also been marketed in Japan by Daiichi Pharmeceutical Company under the brand name "Brindel" [2] for dementia, but was withdrawn in 1999, following a review by the Japanese regulatory authorities of dementia drugs after a drug, calcium hopantenate, that had been considered the standard of care and against which cinepazide and other dementia drugs had been compared, had failed to demonstrate efficacy in a re-evaluation. [12]
In 2002 Sihuan Pharmaceutical brought an injectable form of the drug to market in China; [13] Sihuan had acquired the drug from a military hospital in China that had developed the formulation. [14] In 2010 it was the highest selling drug in China, with about 1 billion RMB in sales in the 3rd quarter, outselling Plavix in China. [13] [3] This made Sihuan Pharm the largest company in China in the cardio-cerebral vascular drug market in 2010. [3] In 2014 it was the tenth highest-selling drug in China. [14]
![]() | |
Clinical data | |
---|---|
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.041.739 |
Chemical and physical data | |
Formula | C22H31N3O5 |
Molar mass | 417.506 g·mol−1 |
3D model ( JSmol) | |
| |
| |
![]() ![]() |
Cinepazide or cinepazide maleate [1] (Kelinao or Anjieli in China [2] [3]) is a vasodilator used in China for the treatment of cardiovascular and cerebrovascular diseases, and peripheral vascular diseases. [4] It appears to work by potentiating A2 adenosine receptors. [5]
Cinepazide was discovered by scientists at Laboratoires Delalande (now part of Sanofi) in 1969 in an effort to explore useful substituted cinnamoyl- piperazine compounds. [6] [7] The drug, in the form of a pill taken orally, was launched by Delalande in 1976 under the tradename Vasodistal, for treatment of heart failure, balance disorders, cerebrovascular disease, and vascular complications of diabetes. [6] [8] In 1988 the drug was withdrawn from the market in Spain due to risk of agranulocytosis; other countries where the drug was available added warnings to the label. [9] [10] It was withdrawn from the market in France in 1992. [11] The drug had also been marketed in Japan by Daiichi Pharmeceutical Company under the brand name "Brindel" [2] for dementia, but was withdrawn in 1999, following a review by the Japanese regulatory authorities of dementia drugs after a drug, calcium hopantenate, that had been considered the standard of care and against which cinepazide and other dementia drugs had been compared, had failed to demonstrate efficacy in a re-evaluation. [12]
In 2002 Sihuan Pharmaceutical brought an injectable form of the drug to market in China; [13] Sihuan had acquired the drug from a military hospital in China that had developed the formulation. [14] In 2010 it was the highest selling drug in China, with about 1 billion RMB in sales in the 3rd quarter, outselling Plavix in China. [13] [3] This made Sihuan Pharm the largest company in China in the cardio-cerebral vascular drug market in 2010. [3] In 2014 it was the tenth highest-selling drug in China. [14]